Sunday, 18 March 2012

Cost Body Backs Novartis-National Institute-Multiple Sclerosis-Pill Gilenya-Novartis Ag

Cost body backs Novartis MS pill in about-turn

LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its top new drug hopes, has been recommended for use in the state health service after a change of heart by the country's healthcare cost-effectiveness watchdog. Friday's verdict from the National Institute for Health and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, is welcome news for a product that has run into problems recently. ... read more..

No comments:

Post a Comment